Allogene Therapeutics Inc Revenue Growth Rates (ALLO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Allogene Therapeutics Inc   (NASDAQ: ALLO)
 

ALLO's Revenue Growth by Quarter and Year

Allogene Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALLO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 5.34
1st Quarter March 0.80
FY 6.14

ALLOs Annual Revenue
Allogene Therapeutics Inc 's Revenue in the fiscal year 2025 $ 0.00 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2024 $ 0.02 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.10 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.16 millions
Allogene Therapeutics Inc 's Revenue in the fiscal year 2021 $ 38.49 millions




ALLO Revenue second quarter 2026 Y/Y Growth Comment
Allogene Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue surge of 567.5% year on year, to $ 5.34 millions.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue growth. While Allogene Therapeutics Inc ' s Revenue doubling of 567.5% ranks overall at the positon no. 75 in the second quarter 2026.


ALLO Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - - - -20 %
2nd Quarter June 567.5 % - - -55.56 %
1st Quarter March 166.67 % 1400 % -60 % -16.67 %
FY   - 8900 % -77.78 % -

Financial Statements
Allogene Therapeutics Inc 's second quarter 2026 Revenue $ 5.34 millions ALLO's Income Statement
Allogene Therapeutics Inc 's second quarter 2025 Revenue $ 0.80 millions Quarterly ALLO's Income Statement


ALLO Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - - - -
3rd Quarter September - -12.5 % - 0 %
2nd Quarter June 567.5 % 166.67 % - -20 %
1st Quarter March - - - 0 %
FY (Year on Year)   - 8900 % -77.78 % -


Back to ALLO Growth rate Comparisons >> Back to ALLO Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #25
Overall #75

Revenue Y/Y Growth Statistics
High Average Low
1263.64 % 127.08 % -100 %
 
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #25
Overall #75
Revenue Y/Y Growth Statistics
High Average Low
1263.64 % 127.08 % -100 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Allogene Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
567.5 % 29.58 % -100 %
(Jun 30 2026)  


ALLO's II. Quarter Q/Q Revenue Comment
Allogene Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 567.5%, to $ 5.34 millions, from $0.80 millions in the first quarter.
ALLO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Allogene Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 44.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #17
Overall #44
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #17
Overall #44
Revenue Q/Q Growth Statistics
High Average Low
567.5 % 29.58 % -100 %
(Jun 30 2026)  


ALLO's II. Quarter Q/Q Revenue Comment
Allogene Therapeutics Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 567.5%, to $ 5.34 millions, from $0.80 millions in the first quarter.
ALLO is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Allogene Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 44.


Allogene Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Jun 30 2026 period, Allogene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Allogene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Jun 30 2026 period, Allogene Therapeutics Inc 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Allogene Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALLO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Abeona Therapeutics Inc 697.48%$ 697.477 millions
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions
Vistagen Therapeutics Inc 504.92%$ 504.918 millions
Kymera Therapeutics Inc 466.40%$ 466.399 millions
Surrozen Inc 408.65%$ 408.647 millions
Regenxbio Inc 405.73%$ 405.731 millions
Insmed Inc393.78%$ 393.775 millions
Omeros Corporation387.10%$ 387.096 millions
Catheter Precision Inc 380.66%$ 380.660 millions
Macrogenics Inc 377.97%$ 377.974 millions
Vireo Growth Inc.335.47%$ 335.470 millions
Dianthus Therapeutics Inc 294.30%$ 294.301 millions


About Allogene Therapeutics Inc Revenue Growth Rates (ALLO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Allogene Therapeutics Inc (CIK 1737287).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-056213
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Allogene Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.